Abbott Laboratories is a global healthcare company that specializes in the development of a wide range of medical devices, diagnostics, nutrition products, and pharmaceuticals. The company focuses on innovation to improve patient outcomes and enhance the quality of life for individuals worldwide. Abbott is known for its advancements in areas such as cardiovascular care, diabetes management, and nutrition science, providing essential tools and solutions that support healthcare professionals and patients in managing various health conditions. With a strong commitment to research and development, Abbott continually seeks to address unmet medical needs and contribute to the advancement of healthcare globally. Read More
Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact Sciences acquisition and boosting ABT shares.
Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters.
The company reaffirmed its full-year compara
Abbott Laboratories (NYSE:ABT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts
Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to ...
Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.
Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for investors weighing portfolio strategy.
